Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
Hutchmed goes pivotal with HMPL-760 in B-cell lymphoma.
The Japanese group pays $315m to co-develop an asset Vir got from a low-cost Sanofi deal.
Solstice Oncology acquires porustobart from Harbour Biomed.
But is Rybrevant deep enough, and does ficerafusp use the right pivotal dose?
2026’s first big oncology buyout is here.
Darovasertib data are promised for the last week of March.
